{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:47Z","timestamp":1790796227722,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors including nivolumab, an antibody against programmed death-1, have been increasingly introduced in various cancer treatment regimens, and are reported to be associated with immune-related adverse events. Nivolumab-induced renal injury is generally caused by acute interstitial nephritis and is managed by drug discontinuation and steroid therapy. Although this agent can infrequently induce glomerulonephritis, the pathogenesis and therapeutic strategy remain undetermined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 78-year-old man was diagnosed with advanced gastric cancer with portal thrombosis. First- and second-line chemotherapies were ineffective; thus, nivolumab monotherapy was initiated. Although it effectively prevented tumor growth, proteinuria and microhematuria appeared 2 months later. Despite drug discontinuation, serum creatinine progressively increased from 0.72 to 1.45\u200amg\/dL. Renal biopsy revealed mesangial IgA and C3 deposition in immunofluorescence analysis and mesangial proliferation with crescent formation in light microscopy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with IgA nephropathy. Based on the temporal relationship between the nivolumab therapy and abnormal urinalysis, IgA nephropathy was considered to have been induced by nivolumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>A moderate dose (0.6\u200amg\/kg\/day) of prednisolone was orally administrated, with tapering biweekly.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Steroid therapy stabilized his serum creatinine levels and markedly reduced proteinuria. However, bacterial pneumonia substantially impaired his performance status; thus, nivolumab could not be restarted despite tumor regrowth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>IgA nephropathy should be recognized as an uncommon renal adverse event during nivolumab therapy. After drug discontinuation, nivolumab-induced IgA nephropathy is likely to respond to moderate doses of steroid therapy with early tapering. However, more evidence is needed to determine whether nivolumab can be safely restarted during or after steroid therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020464","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T03:20:23Z","timestamp":1590636023000},"page":"e20464","source":"Crossref","is-referenced-by-count":17,"title":["Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4767-5892","authenticated-orcid":false,"given":"Katsuyuki","family":"Tanabe","sequence":"first","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahira","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2013.06.010","article-title":"Tubulointerstitial injury associated with chemotherapeutic agents","volume":"21","author":"Shirali","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2015.30","article-title":"New drug toxicities in the onco-nephrology world","volume":"87","author":"Perazella","year":"2015","journal-title":"Kidney Int"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R5-20240521","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/cas.12695","article-title":"Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy","volume":"106","author":"Adachi","year":"2015","journal-title":"Cancer Sci"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ (Clinical research ed)"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","article-title":"Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis","volume":"23","author":"Suzuki","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"R17-20240521","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor-associated glomerulonephritis","volume":"4","author":"Ashour","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:04:57Z","timestamp":1716321897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020464"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":18,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020464","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}